This morning we watched Viatris rise 1.5% to a price of $9.05 per share. The large-cap Medicinal Chemicals company is now trading -38.77% below its average target price of $14.78. Analysts have set target prices ranging from $10.0 to $35.0 per share for Viatris, and have given the stock an average rating of hold.
The stock has an average amount of shares sold short at 3.4%, and a short ratio of 4.02. The company's insiders own 0.32% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 78.2% of Viatris's shares being owned by this investor type.
Institutions Invested in Viatris
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Vanguard Group Inc | 12% | 144,495,498 | $1,307,684,284 |
| 2023-06-30 | Blackrock Inc. | 7% | 88,920,820 | $804,733,437 |
| 2023-06-30 | Davis Selected Advisers, LP | 5% | 62,948,155 | $569,680,814 |
| 2023-06-30 | State Street Corporation | 5% | 61,286,707 | $554,644,710 |
| 2023-06-30 | Price (T.Rowe) Associates Inc | 4% | 48,499,366 | $438,919,271 |
| 2023-06-30 | Geode Capital Management, LLC | 2% | 26,600,284 | $240,732,575 |
| 2023-06-30 | Camber Capital Management LP | 2% | 22,500,000 | $203,625,004 |
| 2023-06-30 | Invesco Ltd. | 2% | 22,300,746 | $201,821,755 |
| 2023-06-30 | Deerfield Management Company, L.P. (Series C) | 1% | 17,703,484 | $160,216,533 |
| 2023-06-30 | Pacer Advisors, Inc. | 1% | 15,661,796 | $141,739,256 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Viatris.
